Dr Ashley Yocum speaks to ecancer about the Beat AML master trial.
The goal of this study is to develop better individualised treatments for patients diagnosed with AML.
The study is a precision medicine master study that assigns newly diagnosed or relapsed or refractory patients with AML to a biomarker-specific treatment within seven days based on targeted genomic sequencing in cytogenetics.
Dr Yocum says that the trial showed that patients had favourable outcomes if they received intensive chemotherapy over the other two treatment options in the study.
She also discusses some of the sub-studies from this trial presented at ASH 2023.